Edesa Biotech is a biotechnology business based in the US. Edesa Biotech shares (EDSA) are listed on the NASDAQ and all prices are listed in US Dollars. Edesa Biotech employs 16 staff and has a trailing 12-month revenue of around $500.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $0.86 |
|---|---|
| 52-week range | $0.76 - $2.81 |
| 50-day moving average | $0.84 |
| 200-day moving average | $1.12 |
| Wall St. target price | $8.33 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.36 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.8567 from 2023-09-20
| 1 week (2023-09-15) | -4.81% |
|---|---|
| 1 month (2023-08-22) | 3.22% |
| 3 months (2023-06-22) | 0.79% |
| 6 months (2023-03-22) | -17.63% |
| 1 year (2022-09-22) | -42.50% |
|---|---|
| 2 years (2021-09-22) | -89.60% |
| 3 years (2020-09-22) | 7.49 |
| 5 years (2018-09-21) | 8.22 |
| Revenue TTM | $500 |
|---|---|
| Gross profit TTM | $311,200 |
| Return on assets TTM | -44.92% |
| Return on equity TTM | -96.18% |
| Profit margin | 0% |
| Book value | $0.38 |
| Market Capitalization | $17.7 million |
TTM: trailing 12 months
We're not expecting Edesa Biotech to pay a dividend over the next 12 months.
Edesa Biotech's shares were split on a 1:6 basis on 9 June 2019. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Edesa Biotech shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Edesa Biotech shares which in turn could have impacted Edesa Biotech's share price.
Over the last 12 months, Edesa Biotech's shares have ranged in value from as little as $0.76 up to $2.81. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Edesa Biotech's is 0.747. This would suggest that Edesa Biotech's shares are less volatile than average (for this exchange).
Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that is in Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada. .
Everything we know about the Discord IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.